Neonatal hemochromatosis

Background

• Neonatal hemochromatosis (NH) is a clinical syndrome of severe neonatal liver disease with extrahepatic iron deposition (siderosis). Nearly all cases are caused by gestational alloimmune liver disease (GALD), a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack fetal hepatocytes, and activate complement-mediated destruction. NH/GALD is the leading treatable cause of neonatal acute liver failure and carries >90% mortality without treatment. The emergency physician must recognize the pattern of liver failure at birth with massively elevated ferritin and AFP, initiate IVIG empirically, and arrange double-volume exchange transfusion and urgent hepatology/neonatology consultation.
• Not a hereditary hemochromatosis — despite the name, NH is an alloimmune disease, not a genetic iron storage disorder
• Incidence: approximately 4 per 100,000 live births in the US; extremely rare globally (<1 per 1,000,000)
• GALD accounts for ~95% of NH cases

Mechanism

• Mother becomes sensitized to a fetal hepatocyte surface antigen (the specific antigen remains unidentified)
• Maternal IgG antibodies cross the placenta (actively transported from ~18 weeks gestation)
• IgG binds fetal hepatocytes → activates terminal complement cascade (C5b-9) → hepatocyte injury and death
• Massive hepatocyte loss → liver failure, congenital cirrhosis
• Secondary iron overload occurs because:
  • Damaged hepatocytes release stored iron
  • Impaired hepatic hepcidin production → unregulated iron absorption
  • Iron deposits in extrahepatic organs (pancreas, myocardium, thyroid, salivary glands) in a pattern that spares the reticuloendothelial system (spleen, lymph nodes, bone marrow are not iron-laden — this distinguishes NH from transfusional iron overload)

Recurrence risk

• 80-95% recurrence in subsequent pregnancies — this is critical information for family counseling
• Maternal IVIG during pregnancy (weekly from 18 weeks gestation) reduces recurrence to 5-10% with nearly 100% healthy live births
• First affected pregnancy is not predictable; typically unrecognized until the affected neonate presents

Clinical features

Presentation at birth or within hours

• Most NH infants are symptomatic at birth or within the first hours of life — this distinguishes NH from most other causes of neonatal liver failure, which typically develop over days to weeks
• Liver failure at birth:
  • Severe conjugated hyperbilirubinemia (total bilirubin may exceed 30 mg/dL)
  • Profound coagulopathy (INR often >3; unresponsive to vitamin K)
  • Hypoalbuminemia
  • Hypoglycemia (impaired hepatic gluconeogenesis)
  • Hyperammonemia
• Ascites and edema
• Hepatomegaly (liver palpable several cm below costal margin; may also be small if severe cirrhosis)
• Oliguria/renal failure (hepatorenal syndrome)

Prenatal findings (may be reported in history)

• Intrauterine growth restriction (IUGR)
• Oligohydramnios
• Hydrops fetalis (in severe cases)
• Stillbirth (NH should be considered in unexplained fetal demise)
• Prematurity (about half of NH infants are preterm)

Characteristic laboratory pattern

The following constellation is highly suggestive of NH:

• Ferritin: massively elevated (typically >800 ng/mL; commonly 2,000-150,000+ ng/mL) — sensitive but not specific, as any severe liver injury elevates ferritin
• Transferrin: low but hypersaturated (saturation often >90-100%) — one of the most characteristic findings
• AFP: very high (typically 100,000-600,000 ng/mL — even higher than neonatal baseline)
• AST/ALT: disproportionately low (often <100 IU/L despite severe liver failure) — this is because there are so few viable hepatocytes remaining that transaminase release is minimal
• INR markedly elevated (often >3)
• Hypoglycemia, hyperammonemia, hypoalbuminemia, metabolic acidosis

Differential diagnosis

Neonatal acute liver failure

• Neonatal herpes simplex (HSV) — the most important alternative diagnosis; start empiric acyclovir alongside IVIG while differentiating (HSV typically presents slightly later, days 7-14, and has markedly elevated AST/ALT, unlike NH)
• Tyrosinemia type 1 — very high AFP + coagulopathy (similar to NH); Fanconi syndrome distinguishes; urine succinylacetone is pathognomonic
• Galactosemia — after initiation of lactose-containing feeds; reducing substances in urine; E. coli sepsis
• Hemophagocytic lymphohistiocytosis (HLH) — fever, hepatosplenomegaly, pancytopenia, hyperferritinemia, hypertriglyceridemia; can closely mimic NH; soluble IL-2 receptor and NK cell activity help distinguish
• Hereditary fructose intolerance — after fructose/sucrose exposure
• Mitochondrial hepatopathy (DGUOK mutations, others)
• Bile acid synthesis defects
• Bacterial sepsis

Key distinguishing features of NH

• Liver failure present at or within hours of birth (most other causes present later)
• AST/ALT disproportionately low for degree of liver failure
• Extrahepatic siderosis (pancreas, heart, thyroid iron-laden on MRI) with splenic sparing
• Ferritin and transferrin saturation massively elevated

Evaluation

ED workup

• Hepatic panel: AST, ALT (expect disproportionately low), bilirubin (fractionate), albumin
• Coagulation studies: PT/INR, fibrinogen
• Ferritin: expect massively elevated (>800 ng/mL; commonly >10,000)
• Iron studies: serum iron, transferrin, transferrin saturation (expect >90%)
• AFP (alpha-fetoprotein): expect markedly elevated
• Blood glucose: frequent monitoring; anticipate hypoglycemia
• Ammonia
• BMP: electrolytes, creatinine (hepatorenal syndrome)
• CBC: thrombocytopenia (common)
• Blood cultures, urinalysis/urine culture — to exclude sepsis
• HSV PCR (blood and CSF if LP feasible) — must exclude HSV empirically
• Lactate

Confirmatory testing for extrahepatic siderosis

• Abdominal MRI (T2-weighted): the most useful diagnostic study
  • Demonstrates low T2 signal in liver and pancreas (iron-laden) with normal/preserved signal in spleen (reticuloendothelial sparing)
  • Can also show iron in myocardium and thyroid
  • Extrahepatic siderosis in pancreas + thyroid is diagnostic of NH
  • Can be performed within hours of birth
• Buccal (minor salivary gland) biopsy:
  • 3-mm punch biopsy of lower lip mucosa (must include submucosal salivary glands)
  • Prussian blue stain reveals hemosiderin in acinar epithelial cells
  • Positive in approximately two-thirds of proven NH cases
  • Minimally invasive; can be performed at bedside even with severe coagulopathy (bleeding controlled by local measures; FFP not required beforehand)
• Liver biopsy: generally avoided due to severe coagulopathy; if performed, shows hepatocyte loss, giant cell transformation, fibrosis/cirrhosis, hepatocyte siderosis with Kupffer cell sparing; C5b-9 immunostaining supports GALD diagnosis
• If either MRI or buccal biopsy demonstrates extrahepatic siderosis → diagnosis of NH is established

Management

Immediate ED management

• Give one dose of IVIG (1 g/kg IV) as soon as NH/GALD is suspected — do not wait for MRI or biopsy confirmation
  • Mechanism: blocks complement-activating antibodies from continuing hepatocyte destruction
  • Current expert recommendation: any neonate in liver failure should receive one dose of IVIG while GALD is being evaluated
• Start empiric IV acyclovir (20 mg/kg/dose every 8 hours) simultaneously — HSV disseminated disease is the most important alternative diagnosis and cannot be reliably excluded clinically; treat for both until testing clarifies
• Correct coagulopathy: FFP, cryoprecipitate (note: coagulopathy in NH is often refractory to vitamin K because it reflects synthetic failure, not vitamin K deficiency)
• Correct hypoglycemia: D10W infusion with frequent glucose monitoring
• IV fluids: cautious volume management (risk of fluid overload with ascites/edema)
• Broad-spectrum antibiotics if sepsis is in the differential

Definitive treatment

• Double-volume exchange transfusion (DVET):
  • Purpose: physically removes circulating maternal IgG antibodies that are driving hepatocyte destruction
  • Performed with twice the calculated blood volume
  • Should be followed immediately by IVIG infusion
• IVIG (1 g/kg IV): given after DVET to block any remaining antibody-induced complement activation
  • May require multiple doses (published cases describe 1-4 doses)
• This combination (DVET + IVIG) has improved survival from ~10-20% (historical) to 75% without liver transplant in the best-reported series
• Do NOT give mother's breast milk — maternal antibodies directed against neonatal hepatocytes may continue to pass through breast milk

Liver transplant

• Consider if patient fails to respond to IVIG ± DVET within days
• NH is a common indication for liver transplantation in the first 3 months of life
• INR recovery may take 4-6 weeks or longer after successful immunotherapy — treatment prevents ongoing immune injury but does not reverse damage already sustained

Therapies of historical interest (largely replaced)

• Antioxidant/chelation cocktail (vitamin E, selenium, N-acetylcysteine, prostaglandin E1, deferoxamine) — used before GALD mechanism was discovered; survival only 10-20%; no longer first-line

Disposition

• All suspected NH cases: NICU admission
• Immediate consultations:
  • Neonatology (DVET, NICU management)
  • Pediatric hepatology/GI (diagnosis confirmation, IVIG, transplant evaluation)
  • Pediatric surgery/transplant center (early notification — emergent transplant may be needed)
• Transfer to a center with neonatal liver transplant capability if not available locally — do not delay IVIG while arranging transfer
• Communicate to the family:
  • 90% recurrence risk in future pregnancies
  • Prenatal IVIG treatment is available and highly effective for preventing recurrence
  • Refer to maternal-fetal medicine for future pregnancy planning

See Also

• Neonatal hepatitis
• Neonatal HSV
• Tyrosinemia
• Galactosemia
• Acute liver failure
• TORCH infections
• Hemochromatosis

External Links

• J Clin Exp Hepatol — Neonatal Hemochromatosis (Feldman & Whitington, 2013)
• AASLD — Little Livers, BIG Problems: Gestational Alloimmune Liver Disease
• Front Pediatr — Efficacy of IVIG/ET Therapy on GALD (2021)
• Medscape — Neonatal Hemochromatosis Workup
• Stanford Children's — Neonatal Hemochromatosis